The seRNA principle and its in vitro and in vivo proof of concept (POC) studies are now published in Nature Communications!

The seRNA platform technology establishes a new treatment modality via selectively expressed RNAs. The functional mechanism of seRNA, its targeting specificity, and its treatment approach as therapeutic modality against cancer (glioblastoma) and viral diseases has now been published.

The publication demonstrates the in vitro and in vivo POC for glioblastoma, as an example of an oncological indication. Additionally, it illustrates the simple adaptation of the seRNA technology to other therapeutic areas and numerous indications.

For more information and details to our unique, proprietary platform, see also:
https://doi.org/10.1038/s41467-024-55547-6